Ashling Wahner

Associate Editor, OncLive

Ashling Wahner joined MJH Life Sciences in 2022. She produces OncLive's podcast, OncLive On Air, and helps ensure timely publication of news content and announcements from the FDA approval pipeline. She also attends conferences live and virtually to conduct video interviews and produce written coverage. Email: awahner@mjhlifesciences.com

Articles

Dr Ruella on the Importance of Clinical Trial and Treatment Accessibility for Myeloma

March 10th 2025

Marco Ruella, MD, discusses ways to develop accessible cancer treatments to more greatly benefit diverse populations of patients with multiple myeloma.

Inavolisib Expands the PIK3CA-Mutated Metastatic HR+ Breast Cancer Treatment Paradigm: With Virginia Kaklamani, MD, DSc

March 10th 2025

Virginia Kaklamani, MD, DSc, discusses the mechanism of action of inavolisib and the importance of the addition of this agent to the HR-positive metastatic breast cancer treatment paradigm.

Neratinib Generates CNS Responses Across HER2+ Breast Cancer Brain Metastases Subgroups

March 10th 2025

Neratinib-containing combinations are consistently effective across CNS end points in patients with HER2-positive breast cancer brain metastases.

Abemaciclib Delivers Consistent Benefit in High-Risk, Early Breast Cancer Regardless of Dose Reductions

March 8th 2025

Patients with high-risk, early breast cancer receiving adjuvant abemaciclib maintained benefit with the agent regardless of dose modification.

International Women’s Day Highlights Importance of Female Mentorship for Early-Career Women in Oncology

March 8th 2025

Megan Melody, MD, discusses her journey as an oncologist and the importance of mentorship and a supportive work environment to empower women in the field.

Abemaciclib/Fulvestrant Improves PFS Across HR+/HER2– Advanced Breast Cancer Subgroups

March 8th 2025

Benefits were seen with abemaciclib/fulvestrant regardless of metastatic site in HER2-negative advanced breast cancer following prior CDK4/6 inhibition.

Dr Meattini on Adjuvant Radiotherapy vs Endocrine Therapy in Early Breast Cancer

March 7th 2025

Icro Meattini, MD, discusses the benefits of adjuvant radiation therapy vs endocrine therapy in patients with luminal-like early breast cancer.

Dr Uboha on the FDA Approval of First-Line Tislelizumab Plus Chemotherapy for Metastatic ESCC

March 7th 2025

Nataliya Uboha, MD, PhD, discusses how the FDA approval of tislelizumab plus chemotherapy addresses unmet needs for patients with metastatic ESCC.

Sacituzumab Govitecan Upholds Efficacy and Safety in Real-World mTNBC Population

March 7th 2025

Treatment with sacituzumab govitecan was effective and tolerable in real-world patients with mTNBC who received the agent in later-line settings.

Ribociclib Efficacy Is Maintained With Dose Reductions in HR+/HER2-Negative Early Breast Cancer

March 7th 2025

A post hoc analysis of the NATALEE trial suggests that ribociclib dose reduction preserves iDFS in hormone receptor+/HER2-negative early breast cancer.

Dr Hinchcliff on the Evolving Role of ADCs in Ovarian Cancer

March 6th 2025

Emily M. Hinchcliff, MD, MPH, discusses the growing role of ADCs like mirvetuximab soravtansine for the treatment of patients with ovarian cancer.

FDA Approval Insights: Vimseltinib for Symptomatic TGCT: With William D. Tap, MD

March 6th 2025

Dr Tap discusses the significance of this approval, key efficacy and safety data from the phase 3 MOTION trial, and the important role that multidisciplinary collaboration will play in integrating this therapy into clinical practice.

Liso-Cel Prolongs Responses, PFS, and OS in Pretreated, High-Risk, R/R CLL

March 6th 2025

Treatment with liso-cel induced long-term CR/CRi rates and high uMRD rates in patients with CLL/SLL following progression on BTK inhibition and venetoclax.

Cell-Free DNA Blood-Based Assay Is Not Superior to Colonoscopy in Colorectal Cancer

March 6th 2025

Sewit Teckie, MD, discusses the advantages and disadvantages of a cfDNA blood-based assay compared with colonoscopy in diagnosing colorectal cancer.

177Lu-edotreotide Radiopharmaceutical Therapy Prolongs PFS vs Everolimus in SSTR+ GEP-NETs

March 6th 2025

Treatment with 177Lu-edotreotide significantly improved PFS and numerically increased OS vs SOC everolimus in grade 1 or 2 SSTR-positive GEP-NETs.

Olverembatinib Plus Chemo Receives Breakthrough Therapy Designation in China for Newly Diagnosed Ph+ ALL

March 6th 2025

First-line olverembatinib plus low-intensity chemotherapy has received breakthrough therapy designation in China for patients with Ph-positive ALL.

Vimseltinib Stands Out as An Alternative to Surgery for Select Patients With Diffuse TGCT

March 6th 2025

R. Lor Randall, MD, FACS, discusses the significance of the FDA approval of vimseltinib for patients with symptomatic TGCT.

Dr Tap on the FDA Approval of Vimseltinib for Symptomatic TGCT

March 5th 2025

William D. Tap, MD, discusses the FDA approval of vimseltinib for patients with symptomatic TGCT and this agent's role in the treatment paradigm.

Vulnerable Conversations Contribute to Patient Advocacy Efforts to Propel Lung Cancer Research: With D. Ross Camidge, MD, PhD; and Tillman Nechtman, PhD

March 5th 2025

Drs Camidge and Nechtman discuss Dr Nechtman's experience supporting and caring for his wife Laura during her lung cancer diagnosis and treatment.

T-DXd’s Role Expands Into HER2-Low/-Ultralow Metastatic Breast Cancer, Reinforcing Need for Enhanced HER2 Testing

March 5th 2025

Aditya Bardia, MD, MPH, FASCO, discusses how the FDA approval of T-DXd for HER2-low/-ultralow metastatic breast cancer has affected the treatment paradigm.